Fresh Fruit
-
Episode 38- ECMO for out-of-hospital cardiac arrest: Is this the future?
This week, we review our medical group's experiences with using ECMO for refractory out-of-hospital cardiac arrests. Is this the future?
-
Episode 37- Updated treatment guidelines for gonococcal infections
There were some pretty significant changes made to the CDC's treatment guidelines for gonococcal infections. Get a quick review here!
-
Episode 34- Adult ACLS: Updated recommendations and clinical pearls
In part 1 of the cardiac arrest series, we review some key recommendations and clinical pearls from the adult 2020 BLS and ACLS guidelines.
-
Episode 33- Shock through the heart: Is two better than one?
What is dual/double defibrillation? How does it work? Does it improve outcomes? Find out this week!
-
Episode 32- Drug shortage debacle: Methohexital or ketamine for RSI
What happens when/ if etomidate goes on shortage? Are methohexital or ketamine viable options for RSI in the ER? Find out this week.
-
Episode 28- Blink and you miss it: an easily missed cause of bradycardia and hypotension
Bradycardic? Hypotensive? Keep the agent discussed in this week's episode in mind when reviewing your patient's medication list.
-
Episode 21- Esmolol in refractory VF arrest
This week we review a meta-analysis that looked at the use of esmolol in patients in refractory VF/pVT arrest. Will this change your practice?
-
Episode 16- “HALT” the use of TXA in GI bleeds?
This week, we review the "HALT-IT" trial. Will you routinely give your patients TXA (tranexamic acid) in the setting of GI bleeds after reading this study?
-
Episode 11- Anaphylaxis: A pharmacologic management update
What is the most important agent for anaphylaxis? What other treatments are only considered as adjuncts? How should I give these agents? Find out this week as we review updated anaphylaxis treatment guidelines published in April 2020!
-
Episode 10- Alteplase door-to-needle times and long-term outcomes
Join us for a quick review on a recently-published study describing the association between alteplase door-to-needle times and long-term patient outcomes in the setting of ischemic stroke.